Version May 2024
| Product name | Half-life (hours)* | Characteristics |
| Standard half-life products¶ | ||
| Advate | 9 to 12 | Recombinant |
| Hemofil M | 15 | Plasma-derived; mAb-purified |
| Kogenate FS | 11 to 15 | Recombinant |
| Koate (previously called Koate DVI) | 16 | Plasma-derived; chromatography-purified |
| Kovaltry | 12 to 14 | Recombinant |
| Novoeight | 8 to 12 | Recombinant |
| Nuwiq | 12 to 17 | Recombinant |
| Recombinate | 15Δ | Recombinant |
| Xyntha | 8 to 11 | Recombinant |
| Longer-lasting products | ||
| Adynovate | 13 to 16 | Recombinant; PEGylated |
| Afstyla | 10 to 14 | Recombinant; single chain |
| Altuviiio | 40 to 48 | Recombinant; Fc-VWF-XTEN fusion |
| Eloctate | 13 to 20 | Recombinant; Fc fusion |
| Esperoct | 17 to 22 | Recombinant, glycoPEGylated |
| Jivi | 17 to 21 | Recombinant; PEGylated |
FS: formulated with sucrose; mAb: monoclonal antibody; Fc: fragment crystallizable; VWF: von Willebrand factor; XTEN: half-life extension polypeptides; PEG: polyethylene glycol.
* Half-lives are approximate. Half-lives are generally shorter for children than adults when assessed in pharmacokinetic studies. The half-life of factor VIII products without modifications to extend half-life is considered to be approximately 12 hours. The half-life should be determined for the individual patient. Refer to product information and institutional guidelines for additional dosing and monitoring information.
¶ Monoclate-P was discontinued in early 2018. Helixate FS manufacturing was discontinued in 2018, with supply available through early 2019.
Δ Adults only.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
